Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02314169 · OUTCOME

Overall Survival (Part B)

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer · Source last updated 2026-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
90% Confidence Interval
Time frame
From initiation of treatment until death, assessed up to 2 years

What was measured

Time measured from initiation of treatment till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 90% confidence interval.

Groups in this outcome

Part B Arm 1 (Nivolumab)

Patients received single-agent Nivolumab IV

Part B Arm II (Nivolumab, Ipilimumab)

Patients received combination Nivolumab and Ipilimumab IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part B Arm 1 (Nivolumab)52
Part B Arm II (Nivolumab, Ipilimumab)48

Reported measurements

Source class 1
Values in months · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Part B Arm 1 (Nivolumab)15.9Not reported11.333.4Not reported
Part B Arm II (Nivolumab, Ipilimumab)20Not reported15.423Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.64
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    90
    ci Upper Limit
    1.51
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    param Type
    Cox Proportional Hazard
    param Value
    0.98
Complete source fields
analyses
  1. ci Lower Limit
    0.64
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    90
    ci Upper Limit
    1.51
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    param Type
    Cox Proportional Hazard
    param Value
    0.98
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.3
        upper Limit
        33.4
        value
        15.9
      2. group Id
        OG001
        lower Limit
        15.4
        upper Limit
        23
        value
        20
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    2. group Id
      OG001
      value
      48
    units
    Participants
description
Time measured from initiation of treatment till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 90% confidence interval.
dispersion Type
90% Confidence Interval
groups
  1. description
    Patients received single-agent Nivolumab IV
    id
    OG000
    title
    Part B Arm 1 (Nivolumab)
  2. description
    Patients received combination Nivolumab and Ipilimumab IV
    id
    OG001
    title
    Part B Arm II (Nivolumab, Ipilimumab)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From initiation of treatment until death, assessed up to 2 years
title
Overall Survival (Part B)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice